Comparative Pharmacology
Head-to-head clinical analysis: EXKIVITY versus NEXAVAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXKIVITY versus NEXAVAR.
EXKIVITY vs NEXAVAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
Multikinase inhibitor targeting Raf, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, Flt-3, and RET kinases, inhibiting tumor growth and angiogenesis.
150 mg orally once daily with or without food.
400 mg (two 200 mg tablets) orally twice daily approximately 12 hours apart on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Terminal half-life 25-48 hours; supports twice-daily dosing with steady state achieved in 7-14 days.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Fecal (77% as unchanged drug and metabolites), renal (19% as metabolites, <1% as unchanged drug).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor